These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Antibiotic treatment of multidrug-resistant organisms in cystic fibrosis. Conway SP; Brownlee KG; Denton M; Peckham DG Am J Respir Med; 2003; 2(4):321-32. PubMed ID: 14719998 [TBL] [Abstract][Full Text] [Related]
4. In vitro antimicrobial activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and other non-fermenting Gram-negative bacteria in adults with cystic fibrosis. Gramegna A; Millar BC; Blasi F; Elborn JS; Downey DG; Moore JE J Glob Antimicrob Resist; 2018 Sep; 14():224-227. PubMed ID: 29559421 [TBL] [Abstract][Full Text] [Related]
5. Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. Saiman L; Chen Y; Gabriel PS; Knirsch C Antimicrob Agents Chemother; 2002 Apr; 46(4):1105-7. PubMed ID: 11897598 [TBL] [Abstract][Full Text] [Related]
6. Activity of innate antimicrobial peptides and ivacaftor against clinical cystic fibrosis respiratory pathogens. Payne JE; Dubois AV; Ingram RJ; Weldon S; Taggart CC; Elborn JS; Tunney MM Int J Antimicrob Agents; 2017 Sep; 50(3):427-435. PubMed ID: 28666755 [TBL] [Abstract][Full Text] [Related]
7. In vitro activity of S-(3,4-dichlorobenzyl)isothiourea hydrochloride and novel structurally related compounds against multidrug-resistant bacteria, including Pseudomonas aeruginosa and Burkholderia cepacia complex. Nicholson A; Perry JD; James AL; Stanforth SP; Carnell S; Wilkinson K; Anjam Khan CM; De Soyza A; Gould FK Int J Antimicrob Agents; 2012 Jan; 39(1):27-32. PubMed ID: 21993484 [TBL] [Abstract][Full Text] [Related]
8. Potential novel therapeutic strategies in cystic fibrosis: antimicrobial and anti-biofilm activity of natural and designed α-helical peptides against Staphylococcus aureus, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia. Pompilio A; Crocetta V; Scocchi M; Pomponio S; Di Vincenzo V; Mardirossian M; Gherardi G; Fiscarelli E; Dicuonzo G; Gennaro R; Di Bonaventura G BMC Microbiol; 2012 Jul; 12():145. PubMed ID: 22823964 [TBL] [Abstract][Full Text] [Related]
9. Comparative evaluation of the effect of different growth media on in vitro sensitivity to azithromycin in multi-drug resistant Pseudomonas aeruginosa isolated from cystic fibrosis patients. Sörensen M; Khakimov B; Nurjadi D; Boutin S; Yi B; Dalpke AH; Eigenbrod T Antimicrob Resist Infect Control; 2020 Dec; 9(1):197. PubMed ID: 33298147 [TBL] [Abstract][Full Text] [Related]
13. Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions. McCaughey G; McKevitt M; Elborn JS; Tunney MM J Cyst Fibros; 2012 May; 11(3):163-72. PubMed ID: 22138067 [TBL] [Abstract][Full Text] [Related]
14. Pitfalls of polymyxin antimicrobial susceptibility testing of Pseudomonas aeruginosa isolated from cystic fibrosis patients. Hogardt M; Schmoldt S; Götzfried M; Adler K; Heesemann J J Antimicrob Chemother; 2004 Dec; 54(6):1057-61. PubMed ID: 15509615 [TBL] [Abstract][Full Text] [Related]
15. Antimicrobial susceptibility profile of molecular typed cystic fibrosis Stenotrophomonas maltophilia isolates and differences with noncystic fibrosis isolates. Cantón R; Valdezate S; Vindel A; Sánchez Del Saz B; Maíz L; Baquero F Pediatr Pulmonol; 2003 Feb; 35(2):99-107. PubMed ID: 12526070 [TBL] [Abstract][Full Text] [Related]
16. Essential Oil from Origanum vulgare Completely Inhibits the Growth of Multidrug-Resistant Cystic Fibrosis Pathogens. Pesavento G; Maggini V; Maida I; Lo Nostro A; Calonico C; Sassoli C; Perrin E; Fondi M; Mengoni A; Chiellini C; Vannacci A; Gallo E; Gori L; Bogani P; Bilia AR; Campana S; Ravenni N; Dolce D; Firenzuoli F; Fani R Nat Prod Commun; 2016 Jun; 11(6):861-4. PubMed ID: 27534136 [TBL] [Abstract][Full Text] [Related]
18. In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010). Farrell DJ; Castanheira M; Mendes RE; Sader HS; Jones RN Clin Infect Dis; 2012 Sep; 55 Suppl 3():S206-14. PubMed ID: 22903953 [TBL] [Abstract][Full Text] [Related]
19. Does Cefiderocol Have a Potential Role in Cystic Fibrosis Pulmonary Exacerbation Management? Gavioli EM; Guardado N; Haniff F; Deiab N; Vider E Microb Drug Resist; 2021 Dec; 27(12):1726-1732. PubMed ID: 34077286 [TBL] [Abstract][Full Text] [Related]
20. In-vitro investigation of the antibacterial activity of agents which may be used for the oral treatment of lung infections in CF patients. Richards RM; Hamilton VE; Thomas MR J Antimicrob Chemother; 1998 Aug; 42(2):171-8. PubMed ID: 9738834 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]